The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance therapy.
Waldenström Macroglobulinemia
DRUG: Thalidomide
Overall response rate, up to 12 months
progress-free survival, up to 36 months
Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and dexamethasone. if a partial remission response or better is achieved, thalidomide plus prednisone maintenance therapy will be given for no more than two years.